Redefining hormone resistance in prostate cancer

Therapeutic Advances in Medical Oncology

Volumn 2, Issue 2, 2010, Pages 107-123

  Hoimes, Christopher J ^a   Kelly, W Kevin ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

androgen receptor signaling; androgen deplete prostate cancer; androgen deplete signaling pathways; castrate resistant prostate cancer; collateral androgen deplete; prostatic adenocarcinoma

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; AMINOGLUTETHIMIDE; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BICALUTAMIDE; DASATINIB; DEGARELIX; DEXAMETHASONE; DUTASTERIDE; ENZASTAURIN; FINASTERIDE; FLUTAMIDE; GESTAGEN; GLUCOCORTICOID; GONADORELIN AGONIST; KETOCONAZOLE; LAPATINIB; NILUTAMIDE; PANOBINOSTAT; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR; STEROID 5ALPHA REDUCTASE INHIBITOR; TEMSIROLIMUS; TESTOSTERONE; UNINDEXED DRUG; VORINOSTAT;

ADRENALECTOMY; ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RELAPSE; CANCER RESISTANCE; CANCER STAGING; CANCER STEM CELL; CASTRATION; CLINICAL TRIAL; DISTANT METASTASIS; DRUG DOSE ESCALATION; GENE MUTATION; HUMAN; HYPOPHYSECTOMY; NOMENCLATURE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 77955640607     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834009356433     Document Type: Review

References (111)

1. Abreu-Martin, M.T., Chari, A., Palladino, A.A., Craft, N.A. and Sawyers, C.L. ( 1999) Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 19: 5143-5154.
2. Ahmann, F.R., Crawford, E.D., Kreis, W. and Levasseur, Y. ( 1987) Adrenal steroid levels in castrated men with prostatic carcinoma treated with aminoglutethimide plus hydrocortisone. Cancer Res 47: 4736-4739.
3. Assikis, V.J., Do, K.-A., Wen, S., Wang, X., Cho-Vega, J.H., Brisbay, S. et al. (2004) Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res 10: 6770-6778.
4. Attard, G., Clark, J., Ambroisine, L., Fisher, G., Kovacs, G., Flohr, P. et al. (2008 b) Duplication of the fusion of Tmprss 2 to Erg sequences identifies fatal human prostate cancer. Oncogene 27: 253-263.
5. Attard, G., Reid, A.H.M., Yap, T.A., Raynaud, F., Dowsett, M., Settatree, S. et al. (2008 a) Phase I clinical trial of a selective inhibitor of Cyp17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26: 2564-4571.
6. Attard, G., Jameson, C., Moreira, J., Flohr, P., Parker, C., Dearnaley, D. et al. (2009 b) Hormone-sensitive prostate cancer: a case of Ets gene fusion heterogeneity. J Clin Pathol 62: 373-376.
7. Attard, G., Reid, A.H.M., A'hern, R., Parker, C., Oommen, N.B., Folkerd, E. et al. (2009 a) Selective inhibition of Cyp 17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27: 3742-3748.
8. Baron, S., Manin, M., Beaudoin, C., Leotoing, L., Communal, Y., Veyssiere, G. et al. (2004) Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-oh kinase in androgen-sensitive epithelial cells. J Biol Chem 279: 14579-14586.
9. Bjorkman, M., Iljin, K., Halonen, P., Sara, H., Kaivanto, E., Nees, M. et al. (2008) Defining the molecular action of hdac inhibitors and synergism with androgen deprivation in Erg-positive prostate cancer. Int J Cancer 123: 2774-2781.
10. Bonaccorsi, L., Carloni, V., Muratori, M., Formigli, L., Zecchi, S., Forti, G. et al. (2004) Egf receptor (Egfr) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Int J Cancer 112: 78-86.
11. Brawn, P.N., Johnson, E.H., Kuhl, D.L., Riggs, M.W., Speights, V.O., Johnson, C.F. et al. (1993) Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer 71: 2569-2573.
12. Bubendorf, L., Kononen, J., Koivisto, P., Schraml, P., Moch, H., Gasser, T.C. et al. (1999) Survey of gene amplifications during prostate cancer progression by high throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 59: 803-806.
13. Buchanan, G., Yang, M., Cheong, A., Harris, J.M., Irvine, R.A., Lambert, P.F. et al. (2004) Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet 13: 1677-1692.
14. Chen, C.D., Welsbie, D.S., Tran, C., Baek, S.H., Chen, R., Vessella, R. et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39.
15. Chiu, C.M., Yeh, S.H., Chen, P.J., Kuo, T.J., Chang, C.J., Chen, P.J. et al. (2007) Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. Proc Natl Acad Sci U S A 104: 2571-2578.
16. Collins, A.T., Berry, P.A., Hyde, C., Stower, M.J. and Maitland, N.J. ( 2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951.
17. Cooperberg, M.R., Grossfeld, G.D., Lubeck, D.P. and Carroll, P.R. ( 2003) National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95: 981-989.
18. Culig, Z., Steiner, H., Bartsch, G. and Hobisch, A. ( 2005) Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr Relat Cancer 12: 229-244.
19. de Bono, J.S., Attard, G., Reid, A.H., Parker, C., Dowsett, M., Mollife, R. et al. (2008) Anti-tumor activity of abiraterone acetate (AA), a Cyp 17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (Crpc). J Clin Oncol (Meeting Abstracts) 26: 5005.
20. Dehm, S.M. and Tindall, D.J. ( 2007) Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol 21: 2855-2863.
21. Demichelis, F., Fall, K., Perner, S., Andren, O., Schmidt, F., Setlur, S.R. et al. (2007) Tmprss2: Erg gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26: 4596-4599.
22. Denmeade, S.R., Lin, X.S. and Isaacs, J.T. ( 1996) Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28: 251-265.
23. Eder, I.E., Culig, Z., Putz, T., Nessler-Menardi, C., Bartsch, G. and Klocker, H. ( 2001) Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur Urol 40: 241-251.
24. Eisenberger, M.A., Laufer, M., Vogelzang, N.J., Sartor, O., Thornton, D., Neubauer, B.L. et al. (2004) Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (Ly320236) in prostate cancer: elevation of estradiol as possible mechanism of action. Urology 63: 114-119.
25. Ellem, S.J. and Risbridger, G.P. ( 2007) Treating prostate cancer: a rationale for targeting local oestrogens. Nat Rev Cancer 7: 621-627.
26. Feldman, B.J. and Feldman, D. ( 2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45.
27. Figg, W.D., Liu, Y., Arlen, P., Gulley, J., Steinberg, S.M., Liewehr, D.J. et al. (2005) A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol 173: 790-796.
28. Fleming, M.T., Sonpavde, G., Kondagunta, G.V., Galsky, M.D., Hutson, T.E. and Sternberg, C.N. (2009) Systemic therapy and novel agents for metastatic castration resistant prostate cancer. Update Cancer Ther 3: 133-145.
29. Freedland, S.J., Eastham, J. and Shore, N. (2009) Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 12: 333-338.
30. Freeman, M.R., Cinar, B. and Lu, M.L. ( 2005) Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab 16: 273-279.
31. Gale, R.P. and Rai, K.R. ( 1987) New insights into a chronic lymphocytic leukemia. Leukemia 1: 677-679.
32. Gu, G., Yuan, J., Wills, M. and Kasper, S. ( 2007) Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 67: 4807-4815.
33. Hanahan, D. and Weinberg, R.A. ( 2000) The hall-marks of cancer. Cell 100: 57-70.
34. Hang, L., Katelyn, M., Joel, S.F. and Matthew, R.S. ( 2005) Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 104: 1633-1637.
35. Harnett, P.R., Raghavan, D., Caterson, I., Pearson, B., Watt, H., Teriana, N. et al. (1987) Aminoglutethimide in advanced prostatic carcinoma. Br J Urol 59: 323-327.
36. Heemers, H.V. and Tindall, D.J. ( 2007) Androgen receptor (Ar) coregulators: a diversity of functions converging on and regulating the Ar transcriptional complex. Endocr Rev 28: 778-808.
37. Huggins, C. and Hodges, C.V. ( 1941) Studies on prostatic cancer - I the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293-297.
38. Huggins, C., Stevens, R.E. and Hodges, C.V. ( 1941) Studies on prostate cancer II the effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43: 209-223.
39. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J. and Thun, M.J. ( 2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
40. Kang, Z., Janne, O.A. and Palvimo, J.J. ( 2004) Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 18: 2633-2648.
41. Kelly, W.K. and Scher, H.I. ( 1993) Prostate specific antigen decline after antiandrogen withdrawal - the flutamide withdrawal syndrome. J Urol 149: 607-609.
42. Kelly, W.K., O'Connor, O.A. and Marks, P.A. ( 2002) Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 11: 1695-1713.
43. Kikuchi, H., Uchida, C., Hattori, T., Isobe, T., Hiramatsu, Y., Kitagawa, K. et al. (2007) Ara 54 Is involved in transcriptional regulation of the cyclin d 1 gene in human cancer cells. Carcinogenesis 28: 1752-1758.
44. Kitahara, S., Umeda, H., Yano, M., Koga, F., Sumi, S., Moriguchi, H. et al. (1999) Effects of intravenous administration of high dose-diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer. Endocr J 46: 659-664.
45. Koivisto, P., Kolmer, M., Visakorpi, T. and Kallioniemi, O.P. ( 1998) Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 152: 1-9.
46. Koivisto, P.A., Schleutker, J., Helin, H., Ehren-Van Eekelen, C., Kallioniemi, O.P. and Trapman, J. ( 1999) Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia. Clin Cancer Res 5: 3578-3582.
47. Labrie, F. ( 2004) Adrenal androgens and intracrinology. Semin Reprod Med 22: 299-309.
48. Lassi, K. and Dawson, N.A. (2009) Emerging therapies in castrate-resistant prostate cancer. Curr Opin Oncol 21: 260-265.
49. Lee, W.H., Morton, R.A., Epstein, J.I., Brooks, J.D., Campbell, P.A., Bova, G.S. et al. (1994) Cytidine methylation of regulatory sequences near the pi-class glutathione s-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A 91: 11733-11737.
50. Lee, P., Zhu, C.C., Sadick, N.S., Diwan, A.H., Zhang, P.S., Liu, J.S. et al. (2005) Expression of androgen receptor coactivator Ara70/Ele1 in androgenic alopecia. J Cutan Pathol 32: 567-571.
51. Li, P., Yu, X., Ge, K., Melamed, J., Roeder, R.G. and Wang, Z. ( 2002) Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol 161: 1467-1474.
52. Loberg, R.D., Bradley, D.A., Tomlins, S.A., Chinnaiyan, A.M. and Pienta, K.J. ( 2007) The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin 57: 225-241.
53. Locke, J.A., Guns, E.S., Lubik, A.A., Adomat, H.H., Hendy, S.C., Wood, C.A. et al. (2008) Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68: 6407-6415.
54. Maitland, N.J. and Collins, A.T. ( 2008) Prostate cancer stem cells: a new target for therapy. J Clin Oncol 26: 2862-2870.
55. Malinowska, K., Neuwirt, H., Cavarretta, I.T., Bektic, J., Steiner, H., Dietrich, H. et al. (2009) Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 16: 155-169.
56. Marcelli, M., Ittmann, M., Mariani, S., Sutherland, R., Nigam, R., Murthy, L. et al. (2000) Androgen receptor mutations in prostate cancer. Cancer Res 60: 944-949.
57. McLeod, D.G., Schellhammer, P.F., Vogelzang, N.J., Soloway, M.S., Sharifi, R., Block, N.L. et al. (1999) Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with Lhrh analogues. Prostate 40: 218-224.
58. Mehra, R., Tomlins, S.A., Yu, J., Cao, X., Wang, L., Menon, A. et al. (2008) Characterization of Tmprss2-Ets gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 68: 3584-3590.
59. Mellado, B., Codony, J., Ribal, M.J., Visa, L. and Gascon, P. (2009) Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway. Clin Trans Oncol 11: 5-10.
60. Meng, M.V., Gary, D.G., Natalia, S., Shilpa, S.M., Deborah, P.L. and Peter, R.C. ( 2002) Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 60: 7-11.
61. Mertz, K.D., Setlur, S.R., Hoshida, Y., Demichelis, F., Lupien, M., Perner, S. et al. (2008) Tmprss2-Erg fusion prostate cancer is a molecularly distinct estrogen-sensitive subclass of aggressive prostate cancer, 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, Nature Publishing Group: Denver, CO.
62. Mestayer, C., Blanchere, M., Jaubert, F., Dufour, B. and Mowszowicz, I. ( 2003) Expression of androgen receptor coactivators in normal and cancer prostate tissues and cultured cell lines. Prostate 56: 192-200.
63. Migliaccio, A., Castoria, G., Di Domenico, M., de Falco, A., Bilancio, A., Lombardi, M. et al. (2000) Steroid-induced androgen receptor-oestradiol receptor beta-src complex triggers prostate cancer cell proliferation. EMBO Journal 19: 5406-5417.
64. Mohler, J.L., Gregory, C.W., Ford, III O.H., Kim, D., Weaver, C.M., Petrusz, P. et al. (2004) The androgen axis in recurrent prostate cancer. Clin Cancer Res 10: 440-448.
65. Montgomery, R.B., Mostaghel, E.A., Vessella, R., Hess, D.L., Kalhorn, T.F., Higano, C.S. et al. (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68: 4447-4454.
66. Mostaghel, E.A., Page, S.T., Lin, D.W., Fazli, L., Coleman, I.M., True, L.D. et al. (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate Cancer. Cancer Res 67: 5403-5041.
67. National Institutes of Health, U., Medicine, N.L.O. and Health and Human Services, U.D.O. (2009) Clinicaltrials.Gov, NIH, NLM, HHS - Clinical Trials Vol. 2009: Bethesda.
68. Need, E.F., Scher, H.I., Peters, A.A., Moore, N.L., Cheong, A., Ryan, C.J. et al. (2009) A Novel androgen receptor amino terminal region reveals two classes of amino / carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin. Endocrinology 150: 2674-2682.
69. Page, S.T., Lin, D.W., Mostaghel, E.A., Hess, D.L., True, L.D., Amory, J.K. et al. (2006) Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 91: 3850-3856.
70. Perner, S., Demichelis, F., Beroukhim, R., Schmidt, F.H., Mosquera, J.M., Setlur, S. et al. (2006) Tmprss2: Erg fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66: 8337-8341.
71. Peterziel, H., Mink, S., Schonert, A., Becker, M., Klocker, H. and Cato, A.C.B. ( 1999) Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 18: 6322-6329.
72. Pienta, K.J. and Bradley, D. ( 2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12: 1665-1671.
73. Pietras, R.J., Arboleda, J., Reese, D.M., Wongvipat, N., Pegram, M.D., Ramos, L. et al. (1995) Her-3 tyrosine kinase pathway targets estrogen-receptor and promotes hormone-independent growth in human breast-cancer cells. Oncogene 10: 2435-2446.
74. Power, R.F., Mani, S.K., Codina, J., Conneely, O.M. and O'Malley, B.W. ( 1991) Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 254: 1636-1639.
75. Pravettoni, A., Mornati, O., Martini, P.G.V., Marino, M., Colciago, A., Celotti, F. et al. (2007) Estrogen receptor beta (erbeta) and inhibition of prostate cancer cell proliferation: studies on the possible mechanism of action in Du 145 cells. Mol Cell Endocrinol 263: 46-54.
76. Raghavan, D. ( 1988) Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol 15: 371-389.
77. Rai, K.R., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy, R.N. and Pasternack, B.S. ( 1975) Clinical staging of chronic lymphocytic leukemia. Blood 46: 219-234.
78. Robinson, D.R., Zylstra, C.R. and Williams, B.O. ( 2008) Wnt signaling and prostate cancer. Curr Drug Targets 9: 571-580.
79. Rosenblatt, A.E. and Burnstein, K.L. (2009) Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic. Mol Endocrinol 23: 412-421.
80. Saramaki, O.R., Harjula, A.E., Martikainen, P.M., Vessella, R.L., Tammela, T.L.J. and Visakorpi, T. ( 2008) Tmprss2:Erg fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 14: 3395-3400.
81. Scher, H.I. and Heller, G. ( 2000) Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 55: 323-327.
82. Scher, H.I. and Kelly, W.K. ( 1993) Flutamide withdrawal syndrome - its impact on clinical-trials in hormone-refractory prostate-cancer. J Clin Oncol 11: 1566-1572.
83. Scher, H.I. and Sawyers, C.L. ( 2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23: 8253-8261.
84. Scher, H.I., Steineck, G. and Kevin Kelly, W. ( 1995) Hormone-refractory (d3) prostate cancer: refining the concept. Urology 46: 142-148.
85. Scher, H.I., Halabi, S., Tannock, I., Morris, M., Sternberg, C.N., Carducci, M.A. et al. (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: 1148-1159.
86. Scher, H.I., Beer, T.M., Higano, C.S., Taplin, M., Efstathiou, E., Anand, A. et al. (2009) Antitumor activity of Mdv 3100 in a phase I / II study of castration-resistant prostate cancer (CRPC). J Clin Oncol (Meeting Abstracts) 27: 5011.
87. Seaton, A., Scullin, P., Maxwell, P.J., Wilson, C., Pettigrew, J., Gallagher, R. et al. (2008) Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 29: 1148-1156.
88. Shah, S.K., Trump, D.L., Sartor, O., Tan, W., Wilding, G.E. and Mohler, J.L. ( 2009) Phase II study of dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol 181: 621-626.
89. Singer, E.A., Golijanin, D.J., Miyamoto, H. and Messing, E.M. ( 2008) Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother 9: 211-228.
90. Small, E.J. and Ryan, C.J. ( 2006) The case for secondary hormonal therapies in the chemotherapy age. J Urol 176: S66-S71.
91. Solit, D.B., Scher, H.I. and Rosen, N. ( 2003) Hsp 90 as a therapeutic target in prostate cancer. Semin Oncol 30: 709-716.
92. Tan, J., Sharief, Y., Hamil, K.G., Gregory, C.W., Zang, D.Y., Sar, M. et al. (1997) Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft Cwr 22 and Lncap cells. Mol Endocrinol 11: 450-459.
93. Tannock, I.F., de Wit, R., Berry, W.R., Horti, J., Pluzanska, A., Chi, K.N. et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512.
94. Taplin, M.E. ( 2007) Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clinl Pract Oncol 4: 236-244.
95. Taplin, M.E., Bubley, G.J., Shuster, T.D., Frantz, M.E., Spooner, A.E., Ogata, G.K. et al. (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate-cancer. N Engl J Med 332: 1393-1398.
96. Tomlins, S.A., Rhodes, D.R., Perner, S., Dhanasekaran, S.M., Mehra, R., Sun, X.W. et al. (2005) Recurrent fusion of Tmprss 2 and Ets transcription factor genes in prostate cancer. Science 310: 644-648.
97. Tomlins, S.A., Laxman, B., Varambally, S., Cao, X., Yu, J., Helgeson, B.E. et al. (2008) Role of the Tmprss2erg gene fusion in prostate cancer. Neoplasia 10: 177-188.
98. Tran, C., Ouk, S., Clegg, N.J., Chen, Y., Watson, P.A., Arora, V. et al. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324: 787-790.
99. van der Kwast, T., Schalken, J., Ruizeveld de Winter, J.A., van Vroonhoven, C.C.J., Mulder, E., Boersma, W. et al. (1991) Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48: 189-193.
100. Veldscholte, J., Risstalpers, C., Kuiper, G., Jenster, G., Berrevoets, C., Claassen, E. et al. (1990) A mutation in the ligand-binding domain of the androgen receptor of human Lncap cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commu 173: 534-540.
101. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg, C. et al. (1995) In-vivo amplification of the androgen receptor gene and progression of human prostate-cancer. Nat Genet 9: 401-406.
102. Vo, N. and Goodman, R.H. ( 2001) Creb-binding protein and P 300 in transcriptional regulation. J Biol Chem 276: 13505-13508.
103. Wang, Y., Kreisberg, J.I. and Ghosh, P.M. ( 2007) Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/akt pathway in prostate cancer. Curr Cancer Drug Targets 7: 591-604.
104. Welsbie, D.S., Xu, J., Chen, Y., Borsu, L., Scher, H.I., Rosen, N. et al. (2009) Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 69: 958-966.
105. Whang, Y.E., Moore, C.N., Armstrong, A.J., Rathmell, W.K., Godley, P.A., Crane, J.M. et al. (2008) A phase II trial of lapatinib in hormone refractory prostate cancer. J Clin Oncol (Meeting Abstracts) 26: 16037.
106. Wu, L.C., Birle, D.C. and Tannock, I.F. ( 2005) Effects of the mammalian target of rapamycin inhibitor Cci-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 65: 2825-2831.
107. Wyatt, R.B., Sanchez-Ortiz, R.F., Wood, C.G., Ramirez, E., Logothetis, C. and Pettaway, C.A. ( 2004) Prognostic factors for survival among caucasian, African-American and hispanic men with androgen-independent prostate cancer. J Nat Med Assoc 96: 1587-1593.
108. Xu, L., Glass, C.K. and Rosenfeld, M.G. ( 1999) Coactivator and corepressor complexes in nuclear receptor function. Cur Opin Genet Devel 9: 140-147.
109. Yeh, S., Kang, H.-Y., Miyamoto, H., Nishimura, K., Chang, H.-C., Ting, H.-J. et al. (1999) Differential induction of androgen receptor transactivation by different androgen receptor coativators in human prostate cancer Du 145 cells. Endocrine 11: 195-202.
110. Yu, E.Y., Wilding, G., Posadas, E., Gross, M., Culine, S., Massard, C. et al. (2008) Dasatinib in patients with hormone-refractory progressive prostate cancer: a phase II study. J Clin Oncol (Meeting Abstracts) 26: 5156.
111. Zhang, Y., Bai, W., Allgood, V.E. and Weigel, N.L. ( 1994) Multiple signaling pathways activate the chicken progesterone receptor. Mol Endocrinol 8: 577-584.